journal article·2025-10-15Open access

Photoacoustic Chemical Imaging of Tumor Microenvironment pH for Prediction of Chemotherapeutic Efficacy in Breast Cancer

Jeff Folz, Janggun Jo, Ahmad Eido, Maria E. Gonzalez, Roberta Caruso, Celina G. Kleer, Xueding Wang

Nano Letters· Volume 25· Issue 41

Abstract

An acidic microenvironment is a hallmark of solid tumors, which occurs due to cancer cells' preferential utilization of aerobic glycolysis. Both in vitro and in vivo studies provide evidence that clinicians can exploit this acidity by selecting drugs whose efficacy is particularly affected by the tumor microenvironment (TME). However, noninvasive measurement of tumor pH remains challenging. Photoacoustic chemical imaging enhanced by pH-sensitive nanoparticles as contrast agents is a promising technique to address this need. This imaging technique was employed to quantitatively monitor the TME pH in mice bearing patient-derived xenografts undergoing simultaneous alkalization treatment and chemotherapy. Compared to controls, in alkalinized tumors, paclitaxel chemotherapy significantly reduced tumor size, increased tumor necrosis, and reduced cancer cell proliferation as validated by histopathology and immunohistochemistry. Thus, photoacoustic chemical imaging of TME pH may provide significant predictive value and represents a promising noninvasive, reliable technology for realizing personalized cancer chemotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Photoacoustic and Ultrasonic Imaging · Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering

University of Michigan

Department of Pathology

University of Michigan Medical School

Rogel Cancer Center

Funding

Rogel Cancer Center, University of Michigan · National Institutes of Health · Prostate Cancer Foundation

References (62)

Show source-provided references
1. 10.1098/rstb.2013.009910.1098/rstb.2013.0099 ↗
2. 10.3390/cancers1209248410.3390/cancers12092484 ↗
3. 10.1007/s10555-018-09778-x10.1007/s10555-018-09778-x ↗
4. 10.1042/BST2016009410.1042/BST20160094 ↗
5. 10.1158/2326-6066.CIR-18-033710.1158/2326-6066.CIR-18-0337 ↗
6. 10.1038/onc.2015.47710.1038/onc.2015.477 ↗
7. 10.1038/nrc171310.1038/nrc1713 ↗
8. 10.1016/j.biopen.2016.01.00110.1016/j.biopen.2016.01.001 ↗
9. 10.1016/j.neo.2019.03.00410.1016/j.neo.2019.03.004 ↗
10. 10.1158/0008-5472.CAN-12-279610.1158/0008-5472.CAN-12-2796 ↗
11. 10.3390/cancers1504132010.3390/cancers15041320 ↗
12. 10.1021/mp200292c10.1021/mp200292c ↗
13. 10.1016/S0006-2952(03)00467-210.1016/S0006-2952(03)00467-2 ↗
14. 10.1016/S0006-2952(03)00468-410.1016/S0006-2952(03)00468-4 ↗
15. 10.1080/15384101.2021.194910610.1080/15384101.2021.1949106 ↗
16. 10.1016/S0022-5347(17)37290-710.1016/S0022-5347(17)37290-7 ↗
17. 10.1016/j.canlet.2010.05.01010.1016/j.canlet.2010.05.010 ↗
18. 10.1159/00035391510.1159/000353915 ↗
19. 10.3390/cancers904003610.3390/cancers9040036 ↗
20. 10.1158/0008-5472.CAN-06-098310.1158/0008-5472.CAN-06-0983 ↗
21. 10.1007/s11307-010-0457-z10.1007/s11307-010-0457-z ↗
22. 10.1039/C5NR06162H10.1039/C5NR06162H ↗
23. 10.1177/153473542092257910.1177/1534735420922579 ↗
24. 10.7554/eLife.1569110.7554/eLife.15691 ↗
25. 10.1021/acsami.3c0973310.1021/acsami.3c09733 ↗
26. 10.1021/acsami.2c1049310.1021/acsami.2c10493 ↗
27. 10.1016/j.jconrel.2019.01.00410.1016/j.jconrel.2019.01.004 ↗
28. 10.1007/s10555-019-09782-910.1007/s10555-019-09782-9 ↗
29. 10.3389/fonc.2022.100358810.3389/fonc.2022.1003588 ↗
30. 10.1158/0008-5472.CAN-07-557510.1158/0008-5472.CAN-07-5575 ↗
31. 10.1021/acs.analchem.8b0479710.1021/acs.analchem.8b04797 ↗
32. 10.1038/s41467-017-00598-110.1038/s41467-017-00598-1 ↗
33. 10.1021/acs.analchem.0c0480410.1021/acs.analchem.0c04804 ↗
34. 10.1002/adma.20150319410.1002/adma.201503194 ↗
35. 10.1016/j.jpap.2024.10024110.1016/j.jpap.2024.100241 ↗
36. 10.1021/acsnano.2c0950210.1021/acsnano.2c09502 ↗
37. 10.3390/bios1310092310.3390/bios13100923 ↗
38. 10.1364/BOE.39337010.1364/BOE.393370 ↗
39. 10.1038/nrclinonc.2012.6110.1038/nrclinonc.2012.61 ↗
40. Swamy M. K. · 2022 · 287
41. 10.3390/ijms23191193710.3390/ijms231911937 ↗
42. 10.18632/oncotarget.1777510.18632/oncotarget.17775 ↗
43. 10.1259/bjro.2023001910.1259/bjro.20230019 ↗
44. 10.1016/j.bspc.2020.10196710.1016/j.bspc.2020.101967 ↗
45. 10.1007/s10334-014-0433-810.1007/s10334-014-0433-8 ↗
46. 10.1007/s11307-016-1029-710.1007/s11307-016-1029-7 ↗
47. 10.1002/nbm.490610.1002/nbm.4906 ↗
48. 10.1038/sj.bjc.669045510.1038/sj.bjc.6690455 ↗
49. 10.1248/bpb.b21-0007610.1248/bpb.b21-00076 ↗
50. 10.21873/anticanres.1402010.21873/anticanres.14020 ↗
51. 10.1038/bjc.1997.20110.1038/bjc.1997.201 ↗
52. 10.1016/j.bbadis.2020.16601110.1016/j.bbadis.2020.166011 ↗
53. 10.1016/B978-0-323-90951-8.00007-210.1016/B978-0-323-90951-8.00007-2 ↗
54. 10.1073/pnas.77.3.156110.1073/pnas.77.3.1561 ↗
55. 10.1016/S0021-9258(19)57363-X10.1016/S0021-9258(19)57363-X ↗
56. 10.3389/fimmu.2024.130258710.3389/fimmu.2024.1302587 ↗
57. 10.1016/j.bcp.2024.11617810.1016/j.bcp.2024.116178 ↗
58. 10.3390/cancers1522549310.3390/cancers15225493 ↗
59. 10.3390/pharmaceutics1302024210.3390/pharmaceutics13020242 ↗
60. Gerweck L. E. · Cancer Res. · 1996 · 56 · 1194
61. 10.1016/S0165-2478(02)00031-710.1016/S0165-2478(02)00031-7 ↗
62. 10.3389/fonc.2022.98171810.3389/fonc.2022.981718 ↗